Health
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
WHIPPANY, N.J., May 15, 2026--AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with mCSPC
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/b01fbb598df97fa5da25412f489d9a9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MisNHoBSPOvxgKCyOEFdlw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/business-wire.com/b01fbb598df97fa5da25412f489d9a9b","width":400,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/4UzbV6D2NpHaXTKtj3_qvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/business-wire.com/b01fbb598df97fa5da25412f489d9a9b","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Primary results from the Phase II ARASEC trial show that NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared to a matched ADT-alone arm from a historical control in the CHAARTED trial","length":384,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ARASEC is a multicenter, open-label trial in U.S. patients designed to be complementary to the pivotal Phase III ARANOTE trial","length":126,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results are being presented today as a plenary session during the American Urological Association (AUA) Annual Meeting","length":118,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":628,"olType":false},{"type":"text","content":"WHIPPANY, N.J., May 15, 2026--(BUSINESS WIRE)--New data from the Phase II ARASEC trial show NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) resulted in a 71% reduction in the risk of progression or death per CHAARTED criteria compared to ADT alone (HR 0.29; 95% CI 0.20–0.40; P<0.001) in U.S. patients (N=320) with metastatic castration-sensitive prostate cancer (mCSPC). NUBEQA plus ADT was also associated with significant improvements in overall survival (OS) (HR 0.50; 95% CI 0.30–0.82; P=0.003), time to metastatic castration-resistant prostate cancer (mCRPC) (HR 0.26; 95% CI 0.18–0.38; P<0.001), and radiological progression-free survival (rPFS) (HR 0.30; 95% CI 0....